Hyosung Ventures Invests in AI-Based Drug Platform "I'mNeuroon"

Strengthening the Future Deep Tech Industry

Hyosung Ventures, the corporate venture capital (CVC) arm of Hyosung, has announced plans to expand its investments in startups in the bio, beauty, and spatial computing sectors. This move is aimed at strengthening its portfolio centered on future deep tech industries.

On May 13, Hyosung Ventures revealed that it had made investments in AAC Holdings, a beauty solutions company, and I'mNeuroon, an artificial intelligence (AI)-based drug discovery platform company.

I'mNeuroon develops drug delivery platforms utilizing AI technology. Based on its proprietary technology that increases the permeability of the blood-brain barrier (BBB), the company has established a competitive edge in the treatment of brain diseases such as Alzheimer's. In February of this year, it also signed a technology transfer agreement with a global pharmaceutical firm.

AAC Holdings is a medical and beauty solutions company specializing in data analytics. The company provides customized care solutions by analyzing customer data, including skin condition and lifestyle habits.

Deepfine is a spatial computing company that digitizes industrial sites into three-dimensional (3D) data. It enables the precise mapping of indoor spaces into 3D maps using standard mobile devices and can be integrated with drones and smart glasses to enhance work efficiency. The company recently won the CES 2025 Innovation Award and is expected to be utilized in industrial applications such as Hyosung Group’s manufacturing sites in the future.

A Hyosung Ventures spokesperson stated, "We are continuously expanding our investments with a focus on promising future industries such as bio, beauty, and spatial computing," adding, "Going forward, we will contribute to activating the domestic deep tech industry ecosystem by maintaining our technology-centered investment approach."